Title : Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy.

Pub. Date : 2020 Jun 15

PMID : 32539832






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Sitagliptin, a DPP-4 inhibitor, has been reported to decrease FABP4 concentration in drug-naive and sulfonylurea-treated patients with type 2 diabetes mellitus. Sitagliptin Phosphate fatty acid binding protein 4 Homo sapiens